On November 16, 2021 ORPHELIA Pharma and K.S. KIM INTERNATIONAL (SK-PHARMA) LTD reported the execution of an exclusive distribution and marketing agreement for Kigabeq (vigabatrin) in the territory of the Russian Federation (Press release, ORPHELIA Pharma, NOV 16, 2021, View Source;utm_medium=rss&utm_campaign=orphelia-pharma-and-k-s-kim-sk-pharma-sign-an-agreement-to-supply-kigabeq [SID1234595693]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kigabeq, the first pediatric form of vigabatrin developed by ORPHELIA Pharma, is notably indicated in the treatment of infantile spasms (West syndrome). Kigabeq is approved in the European Union, where this medicine, intended exclusively for children, benefits from a centralized marketing authorization (Pediatric Use Marketing authorization, PUMA).
"We are delighted to sign this agreement with K.S. KIM, which is based on the value of Kigabeq in paediatrics", says Hugues BIENAYME, Founder and CEO of ORPHELIA Pharma, "With their strong footstep in the distribution of orphan medicines in the Russian territory, K.S. KIM is an excellent partner for Kigabeq."
"With Kigabeq, the only pediatric presentation of vigabatrin, K.S. KIM is expanding its portfolio of drugs intended for rare and serious pathologies in children" adds Dr. Shlomo Sadoun, CEO of K.S. KIM, "Kigabeq is a drug which address unmet medical needs for young patients affected by severe and resistant epilepsies. Our ultimate objective is to register Kigabeq as an orphan drug in Russia, nevertheless we will start distributing it immediately as an unlicenced medicine augmenting unmet needs ".
"Our objective is to make Kigabeq available as widely as possible, so that all children affected by infantile spasms can benefit." concludes Gilles ALBERICI, President of ORPHELIA Pharma, "Thanks to this agreement with K.S. KIM, we are very confident that Russian children suffering from infantile spasms will have access to Kigabeq as quickly as possible."